NovaBay Other Liab vs Total Current Assets Analysis
| NBY Stock | USD 3.44 0.21 5.75% |
NovaBay Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NovaBay Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NovaBay Pharmaceuticals is a good investment. Please check the relationship between NovaBay Pharmaceuticals Other Liab and its Total Current Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.
Other Liab vs Total Current Assets
Other Liab vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NovaBay Pharmaceuticals Other Liab account and Total Current Assets. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between NovaBay Pharmaceuticals' Other Liab and Total Current Assets is -0.07. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of NovaBay Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NovaBay Pharmaceuticals' Other Liab and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of NovaBay Pharmaceuticals are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Other Liab i.e., NovaBay Pharmaceuticals' Other Liab and Total Current Assets go up and down completely randomly.
Correlation Coefficient | -0.07 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Other Liab
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from NovaBay Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Selling General Administrative is likely to rise to about 7.5 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.6M | 7.8M | 7.9M | 8.1M | Total Revenue | 8.4M | 14.4M | 14.7M | 10.0M |
NovaBay Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
NovaBay Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NovaBay Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 11.2M | 15.2M | 24.0M | 16.4M | 9.0M | 14.4M | |
| Total Stockholder Equity | 973K | 12.3M | 10.2M | 10.6M | 3.3M | 5.3M | |
| Other Assets | 477K | 912K | 476K | 489K | 562.4K | 461.6K | |
| Common Stock Shares Outstanding | 618.3K | 1.0M | 1.2M | 1.6M | 4.2M | 4.4M | |
| Liabilities And Stockholders Equity | 11.2M | 15.2M | 24.0M | 16.4M | 9.0M | 14.4M | |
| Other Stockholder Equity | 125.7M | 148.0M | 150.9M | 165.1M | 176.4M | 185.2M | |
| Total Liab | 10.2M | 2.9M | 13.8M | 5.8M | 5.7M | 7.1M | |
| Other Current Liab | 993K | 1.4M | 803K | 917K | 570K | 541.5K | |
| Total Current Liabilities | 5.7M | 2.8M | 3.4M | 4.3M | 4.3M | 4.1M | |
| Property Plant And Equipment Net | 1.4M | 520K | 604K | 2.0M | 1.4M | 1.0M | |
| Net Debt | (2.9M) | (11.4M) | (7.0M) | (3.3M) | (390K) | (409.5K) | |
| Retained Earnings | (125.0M) | (136.1M) | (141.9M) | (158.2M) | (174.8M) | (166.1M) | |
| Accounts Payable | 331K | 302K | 1.0M | 1.1M | 1.1M | 812.7K | |
| Cash | 6.9M | 12.0M | 7.5M | 5.4M | 3.1M | 6.0M | |
| Non Current Assets Total | 1.8M | 996K | 10.8M | 5.1M | 1.9M | 2.0M | |
| Cash And Short Term Investments | 6.9M | 12.0M | 7.5M | 5.4M | 3.1M | 3.0M | |
| Common Stock Total Equity | 154K | 171K | 279K | 418K | 480.7K | 263.6K | |
| Other Current Assets | 105K | 102K | 144K | 113K | 388K | 271.6K | |
| Property Plant And Equipment Gross | 1.4M | 520K | 1.2M | 2.6M | 2.1M | 1.1M | |
| Total Current Assets | 9.4M | 14.2M | 13.2M | 11.3M | 7.2M | 9.5M | |
| Accumulated Other Comprehensive Income | (243K) | (509K) | (560K) | (275K) | (247.5K) | (259.9K) | |
| Common Stock | 279K | 418K | 478K | 652K | 112K | 106.4K | |
| Property Plant Equipment | 110K | 520K | 604K | 2.0M | 1.8M | 1.8M | |
| Other Liab | 2.5M | 560K | 4.1M | 10.1M | 11.6M | 12.2M | |
| Current Deferred Revenue | 822K | 730K | 1.3M | 1.8M | 946K | 1.2M | |
| Non Current Liabilities Total | 4.6M | 87K | 10.4M | 1.6M | 1.4M | 2.6M | |
| Short Term Debt | 3.5M | 416K | 305K | 453K | 1.6M | 1.7M | |
| Non Currrent Assets Other | 77K | 2K | 476K | 489K | 21K | 20.0K | |
| Net Receivables | 1.1M | 1.1M | 1.7M | 2.0M | 759K | 721.1K | |
| Net Tangible Assets | 5.0M | 973K | 12.3M | (237K) | (213.3K) | (202.6K) | |
| Retained Earnings Total Equity | (111.1M) | (115.0M) | (125.0M) | (136.1M) | (122.5M) | (116.3M) | |
| Capital Surpluse | 125.7M | 148.0M | 150.9M | 165.1M | 189.8M | 118.8M | |
| Inventory | 492K | 608K | 3.2M | 3.4M | 2.9M | 3.0M | |
| Non Current Liabilities Other | 198K | 4.6M | 561K | 334K | 300.6K | 285.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NovaBay Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NovaBay Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novabay Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novabay Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for NovaBay Stock analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (120.40) | Revenue Per Share 1.521 | Quarterly Revenue Growth (0.16) | Return On Assets (0.32) | Return On Equity (2.52) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.